<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25316">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02777190</url>
  </required_header>
  <id_info>
    <org_study_id>MSHersheyMC-Shoemaker</org_study_id>
    <nct_id>NCT02777190</nct_id>
  </id_info>
  <brief_title>A Comparison of Oral Misoprostol and Vaginal Misoprostol for Cervical Ripening and Induction of Labor</brief_title>
  <official_title>A Comparison of Oral Misoprostol and Vaginal Misoprostol for Cervical Ripening and Induction of Labor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study if misoprostol administered orally is at least as
      effective as misoprostol administered vaginally for cervical ripening and the induction of
      labor. The main purpose is to show that oral misoprostol administration is non-inferior to
      vaginal misoprostol administration with respect to the time interval from misoprostol
      administration to onset of active phase of labor. The study is a non-inferiority,
      prospective randomized controlled trial comparing oral misoprostol given as 25 mcg every 2
      hours versus vaginal misoprostol given as 25 mcg every 4 hours.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time interval from start of induction of labor (first misoprostol administration) to active phase of labor (greater than or equal to 6 cm cervical dilation).</measure>
    <time_frame>12-24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>time interval from start of induction of labor to initiation of oxytocin for augmentation</measure>
    <time_frame>12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time interval from start of induction of labor to vaginal delivery</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cesarean section rate</measure>
    <time_frame>1-2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of tachysystole</measure>
    <time_frame>1-2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of tachysystole causing non-reassuring fetal heart tones</measure>
    <time_frame>1-2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of need for tocolysis</measure>
    <time_frame>1-2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of chorioamnionitis</measure>
    <time_frame>1-2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of meconium stained fluid</measure>
    <time_frame>1-2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>neonatal morbidity</measure>
    <time_frame>1-2 days</time_frame>
    <description>composite outcome of Apgar score, cord gases, neonatal intensive care unit admission, and/or neonatal death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of anti-emetic use</measure>
    <time_frame>1-2 days</time_frame>
    <description>maternal side effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of diarrhea</measure>
    <time_frame>1-2 days</time_frame>
    <description>maternal side effect</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Labor; Forced or Induced, Affecting Fetus or Newborn</condition>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Oral misoprostol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral misoprostol given 25 mcg every 2 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaginal misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>vaginal misoprostol given 25 mcg every 4 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <arm_group_label>Oral misoprostol</arm_group_label>
    <arm_group_label>Vaginal misoprostol</arm_group_label>
    <other_name>Cytotec</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pregnant Female Patients greater than or equal to 18 years of age

          2. Induction of labor for a single live intrauterine pregnancy

          3. Greater than or equal to 37 weeks gestational age

          4. Cephalic presentation

          5. 20 minute reassuring fetal heart rate (reactive nonstress test (NST))

          6. Bishop score based on sterile vaginal exam of less than or equal to 6, for which the
             cervical dilation is less than or equal to 2 cm.

          7. Equal to 3 or less uterine contractions over 10 minutes

        Exclusion Criteria:

          1. Previous uterine scar

          2. Contraindication to vaginal delivery

          3. Use of magnesium sulfate during administration of misoprostol

          4. Nonreassuring fetal heart tones

          5. Premature rupture of membranes

          6. Uterine tachysystole (greater than 5 contractions in 10 minutes averaged over 30
             minutes)

          7. Suspected intrauterine growth restriction

          8. Fetal anomalies

          9. Contraindication to misoprostol (history of allergy to prostaglandins, glaucoma)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrew Shoemaker, MD</last_name>
    <phone>717-531-3503</phone>
    <email>ashoemaker1@hmc.psu.edu</email>
  </overall_contact>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 18, 2016</lastchanged_date>
  <firstreceived_date>May 17, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Andrew Shoemaker</investigator_full_name>
    <investigator_title>Co-Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>misoprostol</keyword>
  <keyword>cytotec</keyword>
  <keyword>cervical ripening</keyword>
  <keyword>labor, induced</keyword>
  <keyword>active labor</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
